MDM Policy and Practice最新文献

{"title":"Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States.","authors":"Roxane Noharet-Koenig,&nbsp;Katarzyna Lasota,&nbsp;Pascaline Faivre,&nbsp;Edith Langevin","doi":"10.1177/23814683231174432","DOIUrl":"https://doi.org/10.1177/23814683231174432","url":null,"abstract":"<p><strong>Objectives: </strong>Pneumococcal vaccine recommendations have become increasingly complex. This study aims to understand how national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies of 5 European countries and the United States formed their pneumococcal vaccine recommendations, by providing reviewed evidence and key drivers for new recommendations.</p><p><strong>Methods: </strong>Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and National Health Authorities Web sites were screened to capture the evolution of pneumococcal recommendations. A narrative review was conducted on NITAGs and HTA bodies' Web sites. Assessments of pneumococcal vaccines published from 2009 to 2022 were included.</p><p><strong>Results: </strong>Thirty-four records were identified including 21 assessments for risk groups, 17 for elderly, and 12 for children. Burden of disease and vaccine characteristics were almost systematically reviewed during assessments. All 6 countries recommended the use of higher-valent pneumococcal vaccine (PCV; i.e., PCV10 and PCV13) in childhood vaccination programs, given their broader serotype coverage and their comparable profile to PCV7. PCV13 was progressively added to the vaccine schedule (in addition to polysaccharide vaccine) in at least the high-risk group, given the high burden in this population and expected additional benefits of PCV13. For the elderly, unlike the United States, European countries issued negative recommendation for PCV13 routine use because of substantial herd effects from childhood vaccination program making PCV13 likely not cost-effective.</p><p><strong>Conclusions: </strong>This research provides an overview of decision-making processes for higher-valent PCVs recommendations and could be of interest to anticipate the place of next generation of PCVs in the vaccination landscape.</p><p><strong>Highlights: </strong>By describing evidence-based criteria for decision making, this study emphasizes the framework analysis of NITAGs and HTA bodies when assessing pneumococcal vaccines and demonstrates that variation exists between countries and also according to population evaluated.While the burden of disease and immunogenicity/efficacy data were almost systematically reviewed by national stakeholders, economic assessments were reported to a lesser extent but played a major role in the limited use of PCV13 in the adult population.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231174432"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/aa/10.1177_23814683231174432.PMC10233586.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10663612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences for Decision Control among a High-Risk Cohort Offered Lung Cancer Screening: A Brief Report of Secondary Analyses from the Lung Screen Uptake Trial (LSUT).","authors":"Stefanie Bonfield,&nbsp;Mamta Ruparel,&nbsp;Jo Waller,&nbsp;Jennifer L Dickson,&nbsp;Samuel M Janes,&nbsp;Samantha L Quaife","doi":"10.1177/23814683231163190","DOIUrl":"https://doi.org/10.1177/23814683231163190","url":null,"abstract":"<p><p><b>Background.</b> Personal autonomy in lung cancer screening is advocated internationally, but health systems diverge in their approach, mandating either shared decision making (with a health care professional) or individual decision making. Studies of other cancer screening programs have found that individual preferences for the level of involvement in screening decisions vary across different sociodemographic groups and that aligning approaches with individual preferences has the potential to improve uptake. <b>Method.</b> For the first time, we examined preferences for decision control among a cohort of UK-based high-risk lung cancer screening candidates (<i>N</i> = 727). We used descriptive statistics to report the distribution of preferences and chi-square tests to examine associations between decision preferences and sociodemographic variables. <b>Results.</b> Most (69.7%) preferred to be involved in the decision with varying degrees of input from a health care professional. Few (10.2%) wanted to make the decision alone. Preferences were also associated with educational attainment. <b>Conclusion.</b> These findings suggest one-size-fits-all approaches may be inadequate in meeting diverse preferences, particularly those placing sole onus on the individual.</p><p><strong>Highlights: </strong>Preferences for involvement in decision making about lung cancer screening are heterogeneous among high-risk individuals in the United Kingdom and vary by educational attainment.Further work is needed to understand how policy makers might implement hybrid approaches to accommodate individual preferences and optimize lung cancer screening program outcomes.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231163190"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9597017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"To Be or Not to Be\"-Cardiopulmonary Resuscitation for Hospitalized People Who Have a Low Probability of Benefit: Qualitative Analysis of Semi-structured Interviews.","authors":"Daniel Kobewka,&nbsp;Yasmin Lalani,&nbsp;Victoria Shaffer,&nbsp;Tolulope Adewole,&nbsp;Kiefer Lypka,&nbsp;Pete Wegier","doi":"10.1177/23814683231168589","DOIUrl":"https://doi.org/10.1177/23814683231168589","url":null,"abstract":"<p><strong>Purpose: </strong>Our aim was to understand the decision making of patients in hospital who wanted cardiopulmonary resuscitation despite low probability of benefit.</p><p><strong>Methods: </strong>We included patients admitted to general medical wards who had a low chance of surviving in-hospital cardiopulmonary resuscitation (CPR) and had an order in the chart to administer CPR. We developed an interview guide to explore participants' decision-making process, sources of information, and emotions associated with this decision.</p><p><strong>Results: </strong>We developed 3 themes from the data. 1) \"Life is worth living . . . for now\": Participants describe their enjoyment of life and desire to carry on in their current state. 2) \"Making sense of CPR outcomes\": Participants saw CPR outcomes as binary, either they live, or they die; deciding not to receive CPR means choosing death. Participants were optimistic they would survive CPR and cited personal experience and TV as information sources. 3) \"Decision process\": Participants did not engage in shared decision making. Instead, they were asked a binary yes/no question with no reflection on their values or discussion about harms or benefits.</p><p><strong>Limitations: </strong>The probability of successful CPR in our sample is unknown. Findings may be different in a population who is imminently dying but still requesting CPR.</p><p><strong>Conclusions: </strong>Participants chose CPR because they perceived life as worth living and CPR as a chance worth taking. Participants did not want to be left in a severely debilitated state but did not have accurate information about this risk.</p><p><strong>Implications: </strong>Decision making about CPR in-hospital can be improved if it is grounded in accurate risk understanding and the patient's values and wishes.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231168589"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/b7/10.1177_23814683231168589.PMC10141296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inclusive Recruitment Strategies to Maximize Sociodemographic Diversity among Participants: A St. Louis Case Study.","authors":"Chelsey R Carter,&nbsp;Julia Maki,&nbsp;Nicole Ackermann,&nbsp;Erika A Waters","doi":"10.1177/23814683231183646","DOIUrl":"https://doi.org/10.1177/23814683231183646","url":null,"abstract":"<p><p><b>Background.</b> Sociodemographically diverse study samples are critical for research related to health decision making. However, not all researchers have the training, capacity, and funding to engage research methods that recruit the most diverse populations. <b>Objective and Methods.</b> We used participant-generated data, staff salary data, and participant observation to examine the effectiveness and cost of strategies that we used for screening, enrolling, and retaining a sociodemographically diverse sample for a risk communication and behavior change randomized controlled trial. <b>Results.</b> It took approximately 646 hours to contact 1,626 individuals and enroll 554 participants (505 of whom completed the baseline survey; 45.2% were members of a underrepresented racial/ethnic group, 19.4% had no college education, 49.5% were age 30-49 y). Retention at 90-d follow-up was 93%. The total cost was USD$19,898.50. The average cost was $35.92 per participant enrolled. In-person recruitment was most successful in identifying the largest proportion of screened and eligible participants who were members of underrepresented racial/ethnic populations (32.8% and 27.8%, respectively) and with no college experience (39.7% and 33.5%, respectively); it also had the highest total cost ($8,079.17). Existing research pools identified the largest proportion of younger participants (ages 30-49 y; 39.3% and 43.4% for screened and eligible, respectively). Existing listservs yielded the smallest proportion of individuals with no college experience and the fewest members of underrepresented racial/ethnic populations but had the lowest total cost ($290.33). Newspaper ads identified the fewest younger individuals and also had the highest cost per participant enrolled ($166.21). Word of mouth had the lowest cost per participant enrolled ($10.47). <b>Conclusion.</b> Results help medical decision-making researchers formulate recruitment plans that increase sociodemographic diversity in study samples. We also ask funders to accommodate increased costs required to maximize sociodemographic diversity in medical decision-making research.</p><p><strong>Highlights: </strong>We provide concrete strategies for recruiting, enrolling, and retaining a sociodemographically diverse study sample.We offer cost estimates for all stages of study recruitment and found that in-person recruitment was the most effective, but also the most expensive, way to identify Black participants and participants with no college experience.It is critical for investigators to have access to institutional infrastructure and resources to support conducting research that is inclusive of diverse sociodemographic groups.An intentionally diverse recruitment staff supports a diverse study sample.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231183646"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/a9/10.1177_23814683231183646.PMC10334001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10299548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures.","authors":"Heather Davies,&nbsp;Joel Russell,&nbsp;Angel Varghese,&nbsp;Hayden Holmes,&nbsp;Marta O Soares,&nbsp;B Woods,&nbsp;Ruth Puig-Peiro,&nbsp;Stephanie Evans,&nbsp;Rory Tierney,&nbsp;Stuart Mealing,&nbsp;Mark Sculpher,&nbsp;Julie V Robotham","doi":"10.1177/23814683231152885","DOIUrl":"https://doi.org/10.1177/23814683231152885","url":null,"abstract":"<p><p><b>Background.</b> Antimicrobial resistance (AMR) is a global public health threat. The wider implications of AMR, such as the impact of antibiotic resistance (ABR) on surgical procedures, are yet to be quantified. The objective of this study was to produce a conceptual modeling framework to provide a basis for estimating the current and potential future consequences of ABR for surgical procedures in England. <b>Design.</b> A framework was developed using literature-based evidence and structured expert elicitation. This was applied to populations undergoing emergency repair of the neck of the femur and elective colorectal resection surgery. <b>Results.</b> The framework captures the implications of increasing ABR by allowing for higher rates of surgical site infection (SSI) as the effectiveness of antibiotic prophylaxis wanes and worsened outcomes following SSIs to reflect reduced antibiotic treatment effectiveness. The expert elicitation highlights the uncertainty in quantifying the impact of ABR, reflected in the results. A hypothetical SSI rate increase of 14% in a person undergoing emergency repair of the femur could increase costs by 39% (-2% to 108% credible interval [CI]) and decrease quality-adjusted life-years by 11% (0.4% to 62% CI) over 15 y. <b>Conclusions.</b> The modeling framework is a starting point for addressing the implication of ABR on the outcomes and costs of surgeries. Due to clinical uncertainty highlighted in the expert elicitation process, the numerical outputs of the case studies should not be focused on but rather the framework itself, illustration of the evidence gaps, the benefit of expert elicitation in quantifying parameters with limited data, and the potential magnitude of the impact of ABR on surgical procedures. <b>Implications.</b> The framework can be used to support research surrounding the health and cost burden of ABR in England.</p><p><strong>Highlights: </strong>The modeling framework is a starting point for assessing the health and cost impacts of antibiotic resistance on surgeries in England.Formulating a framework and synthesizing evidence to parameterize data gaps provides targets for future research.Once data gaps are addressed, this modeling framework can be used to feed into overall estimates of the health and cost burden of antibiotic resistance and evaluate control policies.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231152885"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/d5/10.1177_23814683231152885.PMC9900655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions.","authors":"J Felipe Montano-Campos,&nbsp;Juan Marcos Gonzalez,&nbsp;Timothy Rickert,&nbsp;Angelyn O Fairchild,&nbsp;Bennett Levitan,&nbsp;Shelby D Reed","doi":"10.1177/23814683221148715","DOIUrl":"https://doi.org/10.1177/23814683221148715","url":null,"abstract":"<p><p><b>Background and Objectives.</b> Risk-tolerance measures from patient-preference studies typically focus on individual adverse events. We recently introduced an approach that extends maximum acceptable risk (MAR) calculations to simultaneous maximum acceptable risk thresholds (SMART) for multiple treatment-related risks. We extend these methods to include the computation and display of confidence intervals and apply the approach to 3 published discrete-choice experiments to evaluate its utility to inform regulatory decisions. <b>Methods.</b> We generate MAR estimates and SMART curves and compare them with trial-based benefit-risk profiles of select treatments for depression, psoriasis, and thyroid cancer. <b>Results.</b> In the depression study, SMART curves with 70% to 95% confidence intervals portray which combinations of 2 adverse events would be considered acceptable. In the psoriasis example, the asymmetric confidence intervals for the SMART curve indicate that relying on independent MARs versus SMART curves when there are nonlinear preferences can lead to decisions that could expose patients to greater risks than they would accept. The thyroid cancer application shows an example in which the clinical incidence of each of 3 adverse events is lower than the single-event MARs for the expected treatment benefit, yet the collective risk profile surpasses acceptable levels when considered jointly. <b>Limitations.</b> Nonrandom sample of studies. <b>Conclusions.</b> When evaluating conventional MARs in which the observed incidences are near the estimated MARs or where preferences demonstrate diminishing marginal disutility of risk, conventional MAR estimates will overstate risk acceptance, which could lead to misinformed decisions, potentially placing patients at greater risk of adverse events than they would accept. <b>Implications.</b> The SMART method, herein extended to include confidence intervals, provides a reproducible, transparent evidence-based approach to enable decision makers to use data from discrete-choice experiments to account for multiple adverse events.</p><p><strong>Highlights: </strong>Estimates of maximum acceptable risk (MAR) for a defined treatment benefit can be useful to inform regulatory decisions; however, the conventional metric considers one adverse event at a time.This article applies a new approach known as SMART (simultaneous maximum acceptable risk thresholds) that accounts for multiple adverse events to 3 published discrete-choice experiments.Findings reveal that conventional MARs could lead decision makers to accept a treatment based on individual risks that would not be acceptable if multiple risks are considered simultaneously.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683221148715"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/fe/10.1177_23814683221148715.PMC9841858.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10604155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond High-Income Countries: Low Numeracy Is Associated with Older Adult Age around the World.","authors":"Wändi Bruine de Bruin,&nbsp;Aulona Ulqinaku,&nbsp;Jimena Llopis,&nbsp;Matteo Santangelo Ravà","doi":"10.1177/23814683231174241","DOIUrl":"https://doi.org/10.1177/23814683231174241","url":null,"abstract":"<p><strong>Background: </strong>Numeracy, or the ability to understand and use numbers, has been associated with obtaining better health and financial outcomes. Studies in high-income countries suggest that low numeracy is associated with older age-perhaps especially among individuals with lower education. Here, we examined whether findings generalize to the rest of the world.</p><p><strong>Methods: </strong>Gallup surveyed >150,000 participants for the 2019 Lloyd's Register Foundation World Risk Poll, from 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries. Low numeracy was operationalized as failing to correctly answer, \"Is 10% bigger than 1 out of 10, smaller than 1 out of 10, or the same as 1 out of 10?\"</p><p><strong>Results: </strong>Regressions controlling for participants' education, income, and other characteristics found that, worldwide, low numeracy was associated with older age, lower education, and their interaction. Findings held in each country-income category, although low numeracy was more common in low-income countries than in high-income countries.</p><p><strong>Limitations: </strong>Age differences may reflect cohort effects and life span-developmental changes.</p><p><strong>Discussion: </strong>Low numeracy is more common among people who are older and less educated. We discuss the need for education and interventions outside of the classroom.</p><p><strong>Highlights: </strong>We analyzed a global survey conducted in 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries.Low numeracy was associated with older adult age, even after accounting for age differences in education.Low numeracy was more common in older people with lower education.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231174241"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/6f/10.1177_23814683231174241.PMC10363889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9875711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review.","authors":"Naazish S Bashir,&nbsp;Avery Hughes,&nbsp;Wendy J Ungar","doi":"10.1177/23814683231156433","DOIUrl":"https://doi.org/10.1177/23814683231156433","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Background.&lt;/b&gt; Policies mandating the use of lower cost biosimilars in patients with inflammatory bowel disease (IBD) have created concerns for patients who prefer their original biologic. &lt;b&gt;Purpose.&lt;/b&gt; To inform the cost-effectiveness of biosimilar infliximab treatment in IBD by systematically reviewing the effect of infliximab price variation on cost-effectiveness for jurisdictional decision making. &lt;b&gt;Data Sources.&lt;/b&gt; MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, Joanna Briggs Institute EBP Database, International Pharmaceutical Abstracts, Health and Psychosocial Instruments, Mental Measurements Yearbook citation databases, PEDE, CEA registry, HTA agencies. &lt;b&gt;Study Selection.&lt;/b&gt; Economic evaluations of infliximab for adult or pediatric Crohn's disease and/or ulcerative colitis published from 1998 through 2019 in which drug price was varied in sensitivity analysis were included. &lt;b&gt;Data Extraction.&lt;/b&gt; Study characteristics, main findings, and results of drug price sensitivity analyses were extracted. Studies were critically appraised. The cost-effective price of infliximab was determined based on the stated willingness-to-pay (WTP) thresholds for each jurisdiction. &lt;b&gt;Data Synthesis.&lt;/b&gt; Infliximab price was examined in sensitivity analysis in 31 studies. Infliximab showed favorable cost-effectiveness at a price ranging from CAD $66 to $1,260 per vial, depending on jurisdiction. A total of 18 studies (58%) demonstrated cost-effectiveness ratios above the jurisdictional WTP threshold. &lt;b&gt;Limitations.&lt;/b&gt; Drug prices were not always reported separately, WTP thresholds varied, and funding sources were not consistently reported. &lt;b&gt;Conclusion.&lt;/b&gt; Despite the high cost of infliximab, few economic evaluations examined price variation, limiting the ability to infer the effects of biosimilar introduction. Alternative pricing strategies and access to treatment could be considered to enable IBD patients to maintain access to their current medications.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;In an effort to reduce public drug expenditures, Canadian and other jurisdictional drug plans have mandated the use of lower cost, but similarly effective, biosimilars in patients with newly diagnosed inflammatory bowel disease or require a nonmedical switch for established patients. This switch has created concerns for patients and clinicians who want to maintain the ability to make treatment decisions and remain with the original biologic.It is customary for economic evaluations to assess the robustness of results to variations in high-cost items such as medications. In the absence of economic evaluations of biosimilars, examining biologic drug price in sensitivity analysis provides insight into the cost-effectiveness of biosimilar alternatives. A total of 31 economic evaluations of infliximab for the treatment of inflammatory bowel disease varied the infliximab price in sensitivity analysis.The infliximab price deemed to be cost-effect","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231156433"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/a3/10.1177_23814683231156433.PMC9969457.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating and Supporting Patient and Caregiver Sensemaking in Complex Medical Decisions Using Participatory Design.","authors":"Sarah Fadem","doi":"10.1177/23814683231164988","DOIUrl":"https://doi.org/10.1177/23814683231164988","url":null,"abstract":"<p><p><b>Background.</b> Patients and caregivers facing complex health decisions must make sense of unfamiliar, emotionally challenging information and experiences. For patients with hematological malignancy, bone marrow transplant (BMT) may be the best chance for a cure but has significant risk of morbidity and mortality. This study aimed to investigate and support patient and caregiver sensemaking as they consider BMT. <b>Methods.</b> Ten BMT patients and 5 caregivers engaged in remote participatory design (PD) workshops. Participants drew timelines of their memorable experiences leading up to BMT. Then, they used transparency paper to annotate their timelines and design improvements to this process. <b>Results.</b> Thematic analysis of drawings and transcripts revealed a 3-phase sensemaking process. In phase 1, participants were introduced to BMT and understood it as a possibility, not an inevitability. In phase 2, they focused on meeting prerequisites including remission and donor identification. Participants came to believe they needed transplant, consequently describing BMT not as a decision between viable options, but that transplant was their \"only chance\" for survival. In phase 3, participants attended an orientation detailing the extensive risks of transplant, leading to anxiety and doubt. Participants designed solutions that provided reassurance to those grappling with the life-altering impacts of transplant. <b>Conclusions.</b> For patients and caregivers navigating complex health decisions, sensemaking is a dynamic, ongoing process that affects expectations and emotional well-being. Interventions targeting reassurance alongside risk information can alleviate emotional impact and facilitate expectation development. The integration of PD and sensemaking methodologies enables participants to create holistic, tangible representations of experiences while empowering stakeholder engagement in intervention design. This method could be applied to other complex medical contexts to understand lived experiences and develop effective support interventions.</p><p><strong>Highlights: </strong>Bone marrow transplant patients and caregivers experienced an evolving, emotionally challenging process of gradually understanding the transplant procedure and its risks.The solutions that participants designed centered on providing reassurance alongside risk information, suggesting future interventions could target emotional support as patients attempt to meet prerequisites and grapple with the risks of the potentially curative procedure.By viewing the challenges of complex medical decisions in terms of sensemaking and applying visual methods such as participatory design, researchers can facilitate expression of the dynamic, multifaceted, emotional components of experience and empower stakeholder involvement in intervention design.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231164988"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/a5/10.1177_23814683231164988.PMC10107376.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9753403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Strategies to Improve Uptake of Expedited Partner Therapy for <i>Chlamydia trachomatis</i> Treatment in Minnesota: A Decision Analytic Model.","authors":"Emily A Groene,&nbsp;Christy M Boraas,&nbsp;M Kumi Smith,&nbsp;Sarah M Lofgren,&nbsp;Meghan K Rothenberger,&nbsp;Eva A Enns","doi":"10.1177/23814683221150446","DOIUrl":"https://doi.org/10.1177/23814683221150446","url":null,"abstract":"<p><p><b>Background.</b> Despite the established effectiveness of expedited partner therapy (EPT) in partner treatment of bacterial sexually transmitted infections (STI), the practice is underutilized. <b>Objective.</b> To estimate the relative effectiveness of strategies to increase EPT uptake (numbers of partners treated for chlamydia). <b>Methods.</b> We developed a care cascade model of cumulative probabilities to estimate the number of partners treated under strategies to increase EPT uptake in Minnesota. The care cascade model used data from clinical trials, population-based studies, and Minnesota chlamydia surveillance as well as in-depth interviews of health providers who regularly treat STI patients and a statewide survey of health providers across Minnesota. <b>Results.</b> Several strategies could improve EPT uptake among providers, including facilitating treatment payment (additional 1,932 partners treated) and implementing electronic health record reminders (additional 1,755 partners treated). Addressing concerns about liability would have the greatest effect, resulting in 2,187 additional partners treated. <b>Conclusions.</b> Providers expressed openness to offering EPT under several scenarios, which reflect differences in knowledge about EPT, its legality, and potential risks to patients. While addressing concerns about provider liability would have the greatest effect on number of partners treated, provider education and procedural changes could make a substantial impact.</p><p><strong>Highlights: </strong>Addressing provider concerns about expedited partner therapy (EPT) legality and its potential risks would result in the most partners treated for chlamydia.EPT alerts and electronic EPT prescriptions may also streamline partner treatment.Provider education about the legality of EPT and its potential risks and training in counseling patients on EPT could also increase uptake.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683221150446"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/f5/10.1177_23814683221150446.PMC9880578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9152183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}